51. M/XDR treatment: toxicity and stigma

Sunday, 06 December 2015, 12:15-13:15

Chair: To be confirmed

Track: Drug-resistant TB care and treatment, including trials

**PC-1132-06**  
**Adverse events among MDR-TB patients receiving second-line treatment in Cubal, Angola**  
Ml Aznar, C Bocanegra, E Gabriel, A Zacarias, I Molina, R De Carvalho, M Moreno, T Lopez (*Spain, Angola*)

**PC-1133-06**  
**QTc interval in patient treated with a 9-month regimen for multidrug-resistant tuberculosis**  

**PC-1134-06**  
**Aminoglycoside ototoxicity in tuberculosis treatment: a review of the World Health Organization global pharmacovigilance database**  
E Sagwa, P.c. Souverein, I Ribeiro, Hgm Leufkens, A Mantel-Teeuwisse (*Namibia*)

**PC-1135-06**  
**The effect of moxifloxacin and clofazimine on the corrected QT interval (QTc) in patients treated with a 9-month regimen for MDR-TB in Niger**  
S Hassane Harouna, A Piubello, B Souleymane, S Morou, I Boukary, A Sala, K G Koura (*Niger, France*)

**PC-1136-06**  
**Hearing thresholds of drug-resistant tuberculosis patients: baseline audiogram configurations and associations**  
M Fadeyi, A Sogebi, V Ibeziako, A Agbaje, E Usoroh, S Dutt, Patr Dakum (*Nigeria*)

**PC-1137-06**  
**Prevalence of depression and anxiety during treatment of MDR-TB patients in a tertiary care hospital**  
Z Barry, Sara Khan, S Khan, O Qureshi, A Pasha, S Rehman, H Hussain, A Malik (*Pakistan*)

**PC-1138-06**  
**Occurrence of adverse events in patient receiving community-based therapy for multidrug-resistant tuberculosis in Pakistan**  
Arsh Javaid, Ma Khan, S Mehreen, A Basit, Khan Afzarafiidi, U Ullah, M Khan (*Pakistan*)

**PC-1139-06**  
**Adolescents’ experiences of multidrug-resistant tuberculosis and of participation in clinical research**  
K Zimri, P Rose, A Garcia-Prats, A Hesseling, H S Schaaf, G Hoddinott, L Viljoen (*South Africa*)

**PC-1140-06**  
**Improving pharmacovigilance of drug-resistant tuberculosis drugs**  
N Misra, I Master (*South Africa*)